Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients

被引:3
|
作者
Sakakibara, Mikio [1 ,2 ,3 ]
Kido, Mitsuhiko [1 ,2 ,4 ]
Kuribayashi, Jun [2 ,4 ]
Okada, Hiroshi [1 ,2 ]
Igarashi, Ataru [5 ]
Kamei, Hiroyuki [3 ]
Nabeshima, Toshitaka [1 ,4 ]
机构
[1] Meijo Univ, NPO Japanese Drug Org Appropriate Use & Res, Fac Pharm, Nagoya, Aichi 4680073, Japan
[2] Meijo Univ, Sugi Pharm Co Ltd, Fac Pharm, Nagoya, Aichi 4680073, Japan
[3] Meijo Univ, Pharmaceut Hosp Lab, Fac Pharm, Nagoya, Aichi 4680073, Japan
[4] Meijo Univ, Dept Reg Pharmaceut Care & Sci, Fac Pharm, Nagoya, Aichi 4680073, Japan
[5] Univ Tokyo, Dept Drug Policy & Management, Grad Sch Pharmaceut Sci, Tokyo, Japan
关键词
Alzheimer disease; Donepezil hydrochloride; Generic drugs; Quality of life; EuroQo1-5; Dimension;
D O I
10.9758/cpn.2015.13.2.174
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: The pharmacological effects of generic (GE) donepezil are the same as Aricept, its brand name counterpart. However, little is known as to whether these two drugs provide the same quality of life (QOL). The study subjects were patients with Alzheimer's disease who were taking donepezil hydrochloride tablets, and were selected by visiting either the local pharmacies or the patients' homes, We chose the brand name drug Aricept and its GE form donepezil to investigate, from a long term caregiver's perspective, the influence of both drugs on the patients' QOL. Methods: An EuroQo1-5 Dimension (EQ-5D) was used to assess the QOL of patients with Alzheimer's disease, before and after various Aricept and/or donepezil regimens, Patients were divided into four groups: first time users of Aricept (n=43), first time users of GE donepezil (n=45), users refilling previous prescriptions of Aricept (n=51), and users switching from Aricept to GE donepezil (n=51). Results: The average change in the EQ-5D utility indices rose significantly in the patients starting a new regimen of Aricept and its GE drug. The patients continuing an existing regimen of Aricept showed no significant differences, even after Aricept was switched to a GE drug. Conclusion: The QOL of patients starting a new regimen of Aricept and its GE drug improved, The QOL was maintained upon switching to the GE drug form.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 50 条
  • [21] Choice of Generic versus Brand-Name Antidepressants in a Regulated Prescription Drug Market: Evidence from Taiwan
    Liu, Ya-Ming
    Ou, Huang-Tz
    Yang, Yen-Kuang
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2014, 17 (04): : 163 - 172
  • [22] Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart
    Kim, Yong Il
    Kim, Jee Hyun
    Lee, Tae Yoon
    Lee, Kyoo Won
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2015, 31 (06) : 335 - 339
  • [24] A Patient with Corneal Epithelial Disorder That Developed after Administration of a Latanoprost Generic, but Not a Brand-Name Drug, Eye Drop
    Takada, Yukihisa
    Okada, Yuka
    Fujita, Norihito
    Saika, Shizuya
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2012, 2012
  • [25] What's in a name? Use of brand vs. generic drug names
    Citrome, L.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (01) : 3 - 4
  • [26] A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major US drug chain pharmacies
    Quon, BS
    Firszt, R
    Eisenberg, MJ
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (06) : 397 - 403
  • [27] Drug treatment of Alzheimer's disease - Effects on caregiver burden and patient quality of life
    Hollister, L
    Gruber, N
    DRUGS & AGING, 1996, 8 (01) : 47 - 55
  • [28] Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drug treatment: a prospective multicenter study in China
    Zhang, S.
    Tao, L.
    Hui, R.
    Zhang, W.
    EUROPEAN HEART JOURNAL, 2018, 39 : 807 - 808
  • [29] Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
    Ross, Joseph S.
    Rohde, Stefanie
    Sangaralingham, Lindsey
    Brito, Juan P.
    Choi, Lauren
    Dutcher, Sarah K.
    Graham, David J.
    Jenkins, Marjorie R.
    Lipska, Kasia J.
    Mendoza, Martin
    Qiang, Yandong
    Wang, Zhong
    Wu, Yute
    Yao, Xiaoxi
    Shah, Nilay D.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (06): : 2305 - 2314
  • [30] THE IMPACT OF MODIFICATIONS OF THE FORMULA FOR GENERIC DRUG PRESCRIPTION RATE ON THE SWITCH TO NEW BRAND-NAME DRUGS WITH SIMILAR THERAPEUTIC USES
    Shimizu, S.
    Imai, S.
    Ishikawa, K. B.
    Ikeda, S.
    Fushimi, K.
    VALUE IN HEALTH, 2014, 17 (07) : A499 - A499